Lava - Model 1207 - Pipeline
From Pipeline
LAVA-1207, a gamma-delta bsTCE targeting the prostate specific membrane antigen (PSMA), has also demonstrated preclinical proof-of-concept. We expect to initiate a Phase I/IIa trial in metastatic castration-resistant prostate cancer in the second half of 2021.
-
Most popular related searches
Product Details
Early-Stage Pipeline
In addition to our two named lead programs, we are advancing a portfolio of early-stage programs.
Customer reviews
No reviews were found for Lava - Model 1207 - Pipeline. Be the first to review!